KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Long-Term Debt Repayments (2019 - 2025)

GoodRx Holdings' Long-Term Debt Repayments history spans 7 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $1.2 million; the TTM value through Dec 2025 reached $5.0 million, down 99.22%, while the annual FY2025 figure was $5.0 million, 99.22% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $1.2 million at GoodRx Holdings, roughly flat from $1.2 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $633.8 million in Q3 2024 and bottomed at $1.2 million in Q1 2025.
  • The 5-year median for Long-Term Debt Repayments is $1.8 million (2021), against an average of $36.9 million.
  • The largest annual shift saw Long-Term Debt Repayments skyrocketed 35970.86% in 2024 before it crashed 99.8% in 2025.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $1.8 million in 2021, then changed by 0.0% to $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then surged by 35970.86% to $633.8 million in 2024, then plummeted by 99.8% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Long-Term Debt Repayments are $1.2 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).